Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Follow-Up Questions
¿Quién es el CEO de Artelo Biosciences Inc?
Mr. Gregory Gorgas es el President de Artelo Biosciences Inc, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción ARTL?
El precio actual de ARTL es de $1.93, ha increased un 3.83% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Artelo Biosciences Inc?
Artelo Biosciences Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Artelo Biosciences Inc?
La capitalización bursátil actual de Artelo Biosciences Inc es $3.8M
¿Es Artelo Biosciences Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Artelo Biosciences Inc, incluyendo 2 fuerte compra, 5 compra, 1 mantener, 0 venta, y 2 fuerte venta
